Introduction and Purpose

People with Atrial Fibrillation (AF) are five times more likely to have a stroke than people unaffected by the condition and AF is a contributing factor to 20% of all strokes in the UK1. Appropriate treatment with anticoagulation reduces the risk of stroke2. NICE CG180 recommend all patients with AF and a CHA2DS2-VASc score of 2 or above should receive oral anticoagulation, taking bleeding risk into account.2

The IPCA programme will focus on the priority objectives for the management of patients with AF as identified by the Academic Health Science Networks (AHSN) – detect, protect and perfect3.

  • Detecting individuals with AF so that all those who need it have access to preventative care
  • Protecting patients by ensuring that all eligible patients have access to treatment with an anticoagulant
  • Perfecting treatment approaches, to ensure optimal treatment for everyone with AF who is receiving an anticoagulant

The programme will be in the form of a service delivered by a third party supplier, Oberoi Consulting and will provide Stroke Prevention in Atrial Fibrillation Audit and Case Finding Service to the selected healthcare organisations. Further information regarding Oberoi Consulting and their Stroke Prevention in Atrial Fibrillation Programme is available to download by clicking here.

Time and availability of resources appear to be barriers to the identification and management of patients with AF. To address this issue, we will also provide practice support overtime funding where required.

Please click here to review further information regarding eligibility and scope of the medical education goods and service grant application.

How to Apply for IPCA - BMS-Pfizer Alliance Medical Education Goods and Services

BMS-Pfizer Alliance invite applications for Stroke Prevention in Atrial Fibrillation (SPAF) and Case Finding Service, with or without practice overtime funding.

To submit your application click here.

Grants will be assessed and awarded on a first come, first served basis subject to availability and any stated criteria. Proposals will be reviewed by appropriate BMS-Pfizer colleagues.

Additional funding may be provided up to the sum of £500 per individual GP practice and £5,000 for larger healthcare organisations to cover practice support overtime to review the project results. Any such funding will be subject to the provision of any and all, written evidence as requested by Pfizer and will be determined at Pfizer’s sole and absolute discretion. Pfizer reserves the right to reject any additional funding request for any reason.


  1. Stroke Association. Available at; accessed May 2019
  2. NICE CG180. AF: management. 2014.; accessed May 2019
  3. London Clinical Networks. AF Toolkit: Detect, Protect and Perfect. Available at Accessed May 2019.